Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00071071
Status:
COMPLETED
Last Update Posted:
2023-05-18
First Post:
2003-10-10
Brief Title:
Clinical Trial of HuMax-CD4 a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin
Sponsor:
Genmab
Organization:
Genmab
Study Overview
Official Title:
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4 a Fully Human Monoclonal Anti-CD4 Antibody in Patients With Refractory or Persistent Early Stage IA-IIA Cutaneous T-Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early stage cutaneous T-cell lymphoma CTCL Almost all participants who are affected by CTCL have cancerous cells which bear a receptor called CD4 HuMax-CD4 is an investigational drug directed against this receptor There is no placebo in this trial all participants will be treated with HuMax-CD4 During the trial the response rates duration of responses relief of symptoms and safety profile of HuMax-CD4 will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None